Brighter’s Actiste® receives final outstanding approval in Qatar
Brighter AB (publ) announced today that the Qatari Transportation and Communication Authority has granted Brighter approval for processing personal data of special nature for both its Actiste® (with insulin injection) and Actiste® Mini devices. With this approval, both Actiste® and Actiste® Mini have been approved for sensitive personal data processing and now have all the regulatory approvals needed for the coming commercialization in Qatar which is, provided that the onboarding process and product customization are finalized, estimated to start in Q4 2021. Brighter announced on 18